Synthetic approaches to 1, 2, 4-triazolo[5, 1-c][1, 2, 4]triazin-7-ones as basic heterocyclic structures of the antiviral drug Riamilovir ("Triazavirin®") active against SARS-CoV-2 (COVID-19). Issue 9 (9th February 2022)

• Record Type: Journal Article
• Authors: Artem'ev, Grigory A.; Rusinov, Vladimir L.; Kopchuk, Dmitry S.; Savchuk, Maria I.; Santra, Sougata; Ulomsky, Eugeny N.; Zyryanov, Grigory V.; Majee, Adinath; Du, Weijie; Charushin, Valery N.; Chupakhin, Оleg N.
• Is Part Of: Organic & biomolecular chemistry. Volume 20:Issue 9(2022)
• Page Start: 1828
• Page End: 1837
• Publication Date: 2022-02-09
• Subjects: Chemistry, Organic -- Periodicals; Bioorganic chemistry -- Periodicals; Chemistry, Physical organic -- Periodicals; 547
• DOI: 10.1039/d1ob02125g
• Languages: English
• ISSNs: 1477-0520

Abstract

Abstract : In this review article, the currently available synthetic approaches to 1, 2, 4-triazolo[5, 1- c ][1, 2, 4]triazin-7-ones have been discussed. This moiety is considered as a basic heterocyclic structure of the antiviral drug Riamilovir ("Triazavirin®"). Abstract : Fragments of 1, 2, 4-triazolo[5, 1- c ][1, 2, 4]triazin-7-one are found in many compounds with various types of biological activities, including the antiviral drug Riamilovir (Triazavirin®), which shows activity against SARS-CoV-2 (COVID-19). Therefore, the development of convenient methods for the synthesis of new derivatives of 1, 2, 4-triazolo[5, 1- c ][1, 2, 4]triazin-7-one is always in demand. This review systematizes the information on the most common synthetic methods for constructing the 1, 2, 4-triazolo[5, 1- c ][1, 2, 4]triazin-7-one heterocyclic system.